Literature DB >> 17404342

Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report.

Mike Clarke1, Sally Hopewell, Iain Chalmers.   

Abstract

OBJECTIVE: Scientific and ethical justification for new clinical trials requires them to have been designed in the light of scientifically defensible assessments of relevant previous research. Reliable interpretation of the results of new clinical trials entails setting them in the context of updates of the reviews upon which they were deemed scientifically and ethically justifiable. We have shown previously that most reports of randomized trials published in five general medical journals in May 1997 and in May 2001 failed to set their results in the context of the findings from similar research. In the current study, we assess whether there had been progress in this respect in 2005 and also investigate the extent to which reports begin by referring to systematic reviews providing the justification for the new research reported.
DESIGN: Assessment of the Introduction and Discussion sections in all reports of randomized trials published during May 2005 in five general medical journals.
SETTING: Reports of randomized trials in five general medical journals. PARTICIPANTS: Annals of Internal Medicine, BMJ, JAMA, Lancet and New England Journal of Medicine.
INTERVENTIONS: None. MAIN OUTCOME MEASURES: The inclusion or mention of one or more systematic reviews in the Introduction or Discussion section of each report assessed.
RESULTS: We found 18 reports of randomized trials. The Introduction sections referred to systematic reviews in five (27%) of these reports. None of the discussion sections of the 15 reports of trials that were not the first published trials to address the question studied placed the results of the new trial in the context of an updated systematic review of other research. Although reference was made to relevant systematic reviews in five of these 15 reports, there was no integration - quantitative or qualitative - of the results of the new trials in an update of these reviews. In the remaining ten reports there was no evidence that any systematic attempt had been made to set the new results in the context of previous trials.
CONCLUSIONS: There is no evidence of progress between 1997 and 2005 in the proportion of reports of trials published in general medical journals which discussed new results within the context of up-to-date systematic reviews of relevant evidence from other controlled trials. Although the proportion of trials referring to systematic reviews in Discussion sections has increased, the majority of reports continued to fail even to do this. Similarly, most researchers appear not to have considered a systematic review when designing their trial. Researchers and journal editors do a disservice to the interests of the public and others involved in healthcare decision-making by acquiescing in this situation.

Entities:  

Mesh:

Year:  2007        PMID: 17404342      PMCID: PMC1847744          DOI: 10.1177/014107680710011415

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  25 in total

1.  Effectiveness of home visitation by public-health nurses in prevention of the recurrence of child physical abuse and neglect: a randomised controlled trial.

Authors:  Harriet L MacMillan; B Helen Thomas; Ellen Jamieson; Christine A Walsh; Michael H Boyle; Harry S Shannon; Amiram Gafni
Journal:  Lancet       Date:  2005 May 21-27       Impact factor: 79.321

2.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

3.  Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.

Authors:  Hakon Hakonarson; Sverrir Thorvaldsson; Anna Helgadottir; Daniel Gudbjartsson; Florian Zink; Margret Andresdottir; Andrei Manolescu; David O Arnar; Karl Andersen; Axel Sigurdsson; Gestur Thorgeirsson; Asgeir Jonsson; Uggi Agnarsson; Halldora Bjornsdottir; Gizur Gottskalksson; Atli Einarsson; Hrefna Gudmundsdottir; Asdis E Adalsteinsdottir; Kolbeinn Gudmundsson; Kristleifur Kristjansson; Thordur Hardarson; Arni Kristinsson; Eric J Topol; Jeffrey Gulcher; Augustine Kong; Mark Gurney; Gudmundur Thorgeirsson; Kari Stefansson
Journal:  JAMA       Date:  2005-05-11       Impact factor: 56.272

4.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.

Authors:  A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

5.  An intervention involving traditional birth attendants and perinatal and maternal mortality in Pakistan.

Authors:  Abdul Hakeem Jokhio; Heather R Winter; Kar Keung Cheng
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

6.  Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

Authors:  Etienne G C Brain; Thomas Bachelot; Daniel Serin; Sylvie Kirscher; Yvon Graic; Jean-Christophe Eymard; Jean-Marc Extra; Martin Combe; Emmanuelle Fourme; Catherine Noguès; Jacques Rouëssé
Journal:  JAMA       Date:  2005-05-18       Impact factor: 56.272

7.  Antioxidant supplementation for the prevention of kwashiorkor in Malawian children: randomised, double blind, placebo controlled trial.

Authors:  Heather Ciliberto; Michael Ciliberto; Andreé Briend; Per Ashorn; Dennis Bier; Mark Manary
Journal:  BMJ       Date:  2005-04-25

8.  Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.

Authors:  Pierre J Guillou; Philip Quirke; Helen Thorpe; Joanne Walker; David G Jayne; Adrian M H Smith; Richard M Heath; Julia M Brown
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

9.  A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.

Authors:  Herbert L DuPont; Zhi-Dong Jiang; Pablo C Okhuysen; Charles D Ericsson; Francisco Javier de la Cabada; Shi Ke; Margaret W DuPont; Francisco Martinez-Sandoval
Journal:  Ann Intern Med       Date:  2005-05-17       Impact factor: 25.391

10.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

View more
  35 in total

1.  Blatant ignorance.

Authors:  B S Chong; A M Berman; G Billis; A M Quinn; C D Emery; G Di Filippo; H F Duncan; E Schäfer; N P Chandler
Journal:  Br Dent J       Date:  2016-02-12       Impact factor: 1.626

2.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

3.  Why promote the findings of single research studies?

Authors:  Paul Wilson; Mark Petticrew; Mike Calnan; Irwin Nazareth
Journal:  BMJ       Date:  2008-03-29

4.  Wanted: early goal-directed therapy for septic shock--dead or alive, but not critically ill!

Authors:  Andre C Kalil
Journal:  Intensive Care Med       Date:  2009-09-18       Impact factor: 17.440

5.  Can we rely on the best trial? A comparison of individual trials and systematic reviews.

Authors:  Paul P Glasziou; Sasha Shepperd; Jon Brassey
Journal:  BMC Med Res Methodol       Date:  2010-03-18       Impact factor: 4.615

6.  Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews.

Authors:  Ferrán Catalá-López; Rafael Tabarés-Seisdedos
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-21       Impact factor: 4.553

7.  Missing the forest (plot) for the trees? A critique of the systematic review in tobacco control.

Authors:  Laura J Rosen; Michal Ben Noach; Elliot Rosenberg
Journal:  BMC Med Res Methodol       Date:  2010-04-25       Impact factor: 4.615

8.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

9.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

10.  The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis.

Authors:  Nynke R van den Broek; Sarah A White; Mark Goodall; Chikondi Ntonya; Edith Kayira; George Kafulafula; James P Neilson
Journal:  PLoS Med       Date:  2009-12-01       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.